Spectrum Pharmaceuticals Inc (NASDAQ:SPPI)

21.16
Delayed Data
As of Feb 16
 -0.47 / -2.17%
Today’s Change
5.47
Today|||52-Week Range
23.50
+11.66%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.1B

Company Description

Spectrum Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It targets non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, acute lymphoblastic leukemia, and multiple myeloma. It operates through the following brands: FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, EVOMELA, EOQUIN, and RenaZorb. The company was founded in December 1987 and is headquartered in Henderson, NV.

Contact Information

Spectrum Pharmaceuticals, Inc.
11500 South Eastern Avenue
Henderson Nevada 89052
P:(702) 835-6300
Investor Relations:

Employees

Shareholders

Individual stakeholders6.36%
Other institutional42.93%
Mutual fund holders42.09%

Top Executives

Joseph W. TurgeonPresident, Chief Executive Officer & Director
Thomas J. RigaChief Operating Officer
Kurt A. GustafsonChief Financial Officer & Executive Vice President
Pramod K. GuptaSenior Vice President-Pharmaceutical Operations
Bimal R. ShahVice President-Corporate & Business Development